Guided Therapeutics (GTHP) Operating Margin (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Operating Margin for 16 consecutive years, with 120.34% as the latest value for Q4 2025.
- Quarterly Operating Margin rose 5327966.0% to 120.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 309.26% through Dec 2025, up 2981931.0% year-over-year, with the annual reading at 309.26% for FY2025, 2980503.0% up from the prior year.
- Operating Margin hit 120.34% in Q4 2025 for Guided Therapeutics, up from 808.33% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 120.34% in Q4 2025 to a low of 53400.0% in Q4 2024.
- Historically, Operating Margin has averaged 11790.73% across 5 years, with a median of 3626.14% in 2023.
- Biggest five-year swings in Operating Margin: tumbled -5188438bps in 2024 and later skyrocketed 5327966bps in 2025.
- Year by year, Operating Margin stood at 725.0% in 2021, then crashed by -5528bps to 40800.0% in 2022, then surged by 96bps to 1515.62% in 2023, then crashed by -3423bps to 53400.0% in 2024, then soared by 100bps to 120.34% in 2025.
- Business Quant data shows Operating Margin for GTHP at 120.34% in Q4 2025, 808.33% in Q3 2025, and 652.14% in Q2 2025.